What FORUS Therapeutics does

FORUS Therapeutics is a Canadian specialty biopharmaceutical company founded in January 2021 and headquartered in Oakville, Ontario. The company commercializes two hematology/oncology assets in Canada: BESREMI (ropeginterferon alfa-2b), a long-acting interferon approved by Health Canada in July 2026 for polycythemia vera (a rare myeloproliferative blood cancer), and XPOVIO (selinexor), a first-in-class oral selective inhibitor of nuclear export (SINE) compound indicated for multiple myeloma. FORUS operates as a wholly-owned subsidiary of PharmaEssentia Corporation following its June 2026 acquisition.

The company's business model centers on in-licensing late-stage or approved oncology assets from global developers — Karyopharm (XPOVIO, January 2021) and PharmaEssentia (BESREMI, October 2024) — and commercializing them exclusively in Canada through the pan-Canadian Pharmaceutical Alliance (pCPA) and provincial drug reimbursement frameworks. Revenue is generated through specialty drug distribution to hematology clinics and oncology centers treating patients with polycythemia vera and relapsed/refractory multiple myeloma. The go-to-market relies on securing provincial formulary listings and reimbursement, with XPOVIO completing pan-Canadian public coverage in November 2025 and BESREMI newly approved in mid-2026.

FORUS is led by CEO Kevin Leshuk, whose prior senior roles at Pfizer, Roche Canada, and Celgene anchor the company's specialty oncology commercialization expertise. The company was initially capitalized with approximately $20M CAD in equity and $2.5M CAD in debt, and its current corporate trajectory is shaped by the PharmaEssentia acquisition, which provides the balance sheet and corporate infrastructure for scaling the Canadian commercial franchise.

Name

FORUS Therapeutics

Legal name

FORUS Therapeutics Inc.

Website

https://forustherapeutics.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

11–50 employees

Short description

FORUS Therapeutics is a Canadian specialty biopharmaceutical company that in-licenses and commercializes approved hematology/oncology drugs — BESREMI for polycythemia vera and XPOVIO for multiple myeloma — exclusively in Canada through provincial drug plans, serving patients with rare blood cancers and myeloma.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals - Oncology/Hematology

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)

Keywords

• Hematology oncology drugs
• Specialty pharmaceuticals
• Cancer therapeutics
• Polycythemia vera treatment
• Multiple myeloma therapy

Headquarters

HQ city

Oakville

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: FORUS generates revenue through the sale of prescription pharmaceutical products (BESREMI and XPOVIO) to healthcare providers, hospitals, and through public/private drug plan reimbursement across Canadian provinces.
2. Licensing Revenue: As a wholly owned subsidiary of PharmaEssentia Corp following acquisition in June 2026, FORUS operates under licensing agreements with PharmaEssentia (BESREMI) and Karyopharm Therapeutics (XPOVIO) for Canadian commercialization rights.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

FORUS Therapeutics commercializes two specialty prescription pharmaceutical products in Canada: BESREMI® (ropeginterferon alfa-2b), a long-acting interferon injection for adults with polycythemia vera, and XPOVIO® (selinexor), an oral XPO1 inhibitor for adults with multiple myeloma. Both drugs are in-licensed from PharmaEssentia and Karyopharm Therapeutics, and FORUS handles Canadian regulatory approvals, market access negotiations with provincial drug plans, medical affairs, and field-based sales to hematologists and oncologists.

Product overview

FORUS Therapeutics is a Canadian specialty pharmaceutical company that commercializes differentiated medicines for hematologic malignancies and cancer. The company operates with two core commercialized products: BESREMI® (ropeginterferon alfa-2b), a long-acting interferon for polycythemia vera obtained through licensing from parent company PharmaEssentia; and XPOVIO® (selinexor), an XPO1 inhibitor for multiple myeloma licensed from Karyopharm Therapeutics. Both products target rare hematologic cancers and are supported by patient assistance programs and market access initiatives across Canadian provinces.

Differentiator

Problem solved

Functional benefit

Products and services

• BESREMI® (ropeginterferon alfa-2b) A monopegylated, long-acting interferon alfa-2b injection for the treatment of adults with polycythemia vera (PV), a rare chronic blood cancer. Administered subcutaneously once every two weeks (or every four weeks with hematological stability). Licensed from PharmaEssentia Corp.
• XPOVIO® (selinexor) A first-in-class oral selective nuclear export (XPO1) inhibitor (SINE) in tablet form, indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Licensed from Karyopharm Therapeutics Inc.
• ForYOU Patient Support Program (PSP) A dedicated patient support service for Canadian patients prescribed FORUS products (notably XPOVIO), assisting with reimbursement navigation, financial assistance, and treatment adherence via phone (1-833-496-8777) and fax.

Quantifiable outcome

• XPOVIO achieved public funding across multiple provinces including Alberta, Saskatchewan, British Columbia, Ontario, Newfoundland and Labrador, New Brunswick, Nova Scotia, PEI, and Quebec
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and minor.

• PharmaEssentia CorporationcoreStrategic or Co-development Partner · 11 June 2026PharmaEssentia acquired FORUS Therapeutics in June 2026, making it a wholly owned subsidiary. FORUS continues to leverage its established expertise in the Canadian hematology and oncology environment while benefiting from expanded global resources and capabilities. The acquisition strengthens the combined organization's ability to support regulatory, medical, market access, and commercial activities across Canada. FORUS previously held exclusive licensing rights for BESREMI (ropeginterferon alfa-2b) for polycythemia vera in Canada.
• Bloom Burton & Co.minorGTM or Marketing PartnerBloom Burton & Co. is a healthcare investor conference organizer. FORUS has presented at multiple Bloom Burton & Co. Healthcare Investor Conferences (2022, 2023) as part of their investor relations and corporate visibility strategy.
• Queen’s University (PHMI Program)minorStrategic or Co-development PartnerFORUS participates in the Pharmaceutical & Healthcare Management and Innovation (PHMI) graduate program at Queen's University, hosting interns through the program as part of talent development and academic engagement.
• Canadian MPN NetworkminorGTM or Marketing PartnerPatient advocacy organization representing myeloproliferative neoplasm (MPN) patients in Canada. Doug Chisholm (former Chair) and Patricia Saluk (current President) have publicly supported BESREMI availability in Canada.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Paladin Labs: Canadian specialty pharmaceutical company now operating as a subsidiary of Endo, specializing in in-licensing, acquiring, and commercializing specialty products in Canada. Strong overlap in business model and Canadian commercialization expertise.
• Verity Pharmaceuticals: Canadian specialty pharmaceutical company focused on women's health and oncology, in-licensing and commercializing products in Canada. Similar in-licensing model and Canadian-only commercial focus, with a relevant oncology overlap.
• Cipher Pharmaceuticals: Canadian specialty pharmaceutical company based in Mississauga that acquires, in-licenses, and commercializes specialty products in Canada. Similar business model of bringing differentiated, often niche, therapies to the Canadian market through licensing partnerships.
• Milestone Pharmaceuticals: Canadian specialty pharmaceutical company commercializing cardiovascular therapies, including an FDA-approved product. While therapeutic focus differs, the model of a Canadian-domiciled specialty pharma commercializing novel, differentiated therapies is directly comparable.
• Knight Therapeutics: Canadian specialty pharmaceutical company headquartered in Montreal that in-licenses and commercializes innovative products in Canada and select emerging markets. Closely comparable to FORUS in business model (in-licensed assets, Canadian commercialization focus) and oncology/hematology overlap.
• Theratechnologies: Canadian specialty biopharmaceutical company focused on oncology and HIV, commercializing in-licensed and proprietary products. Comparable commercial-stage Canadian specialty pharma with a focus on serious conditions and narrow prescriber networks.

Broad incumbents

• Bristol Myers Squibb Canada: Canadian operations of BMS, the parent of former Celgene and a leader in multiple myeloma (Revlimid, Pomalyst, Empliciti). Competes with XPOVIO in multiple myeloma and relevant because FORUS's leadership team largely hails from Celgene Canada.
• Bausch Health: Canadian-headquartered specialty pharmaceutical company with a broad portfolio across dermatology, gastroenterology, and neurology. Operates at significantly larger scale than FORUS but shares the Canadian commercial infrastructure and specialty pharma model.

Others

• PharmaEssentia Corporation: Taiwan-based global biopharmaceutical company (TWSE: 6446) and FORUS's parent since June 2026; originator of BESREMI. Included as the strategic acquirer and primary licensor of FORUS's flagship asset.
• Karyopharm Therapeutics: U.S.-based oncology company that developed XPOVIO (selinexor) and licensed Canadian commercialization rights to FORUS in 2021. Included as the originator of FORUS's other core product and a key licensor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/forus-therapeutics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FORUS Therapeutics